x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011811
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IP, IF |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to a sequence around Pro186 of human ATGL. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PNPLA2 |
| UniProt No. | Q96AD5 |
| Gene ID | 57104 |
| Gene Description | Triglycerides form an important energy store in many living organisms. Adipose tissue serves as the primary storage depot for triglycerides in mammals. Lipolytic enzymes mobilize triglycerides during periods of starvation to provide organisms with necessary energy. Hormone-sensitive lipase, the first identified lipolytic enzyme, hydrolyzes triglycerides in mammalian adipose tissues. Additional lipolytic enzymes, including adipose triglyceride lipase, have also been discovered. The primary function of ATGL is to catalyze the hydrolysis of the first ester bond of lipid molecules. This enzyme may provide diglyceride substrates for HSL hydrolysis. ATGL is abundantly expressed in murine white and brown adipose tissue, and is highly substrate specific. ATGL was independently identified as desnutrin and the TG-hydrolace inducible phospholipase-A2-ζ. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
